



**Lundbeck Media Contact**  
Sally Benjamin Young  
847-282-5570

### **Lundbeck Names Sean Nolan as New CEO of its Lundbeck Inc. U.S. Subsidiary**

DEERFIELD, Ill., December 10, 2009 – H. Lundbeck A/S, Denmark announced today that it has named Sean Nolan chief executive officer of its U.S. business, Lundbeck Inc., succeeding Jeffrey S. Aronin.

Mr. Nolan has been with the company for more than five years in a variety of roles, most recently as chief commercial officer. Following Lundbeck's acquisition of Ovation Pharmaceuticals earlier this year, he led the Lundbeck Inc. integration team charged with the successful and timely integration of Ovation Pharmaceuticals into Lundbeck. In addition to these and other commercial leadership roles, Mr. Nolan served as vice president of product development and global project management, having led and coordinated the alignment of the clinical, regulatory, manufacturing and marketing teams to ensure success in meeting key company central nervous system (CNS) development program milestones. Prior to joining Ovation Pharmaceuticals in 2004, Mr. Nolan worked in the Pharmaceutical Products Division of Abbott Laboratories for 13 years in a variety of marketing and sales management positions in multiple therapeutic areas.

"The integration of Ovation and Lundbeck has been smooth and in line with expectations, and this is in no small part due to Sean's contributions to the process," says Ulf Wiinberg, president and chief executive officer of H. Lundbeck A/S. "Sean has furthermore been responsible for two successful product launches, and with Sean at the helm, I have no doubt that Lundbeck Inc. will continue in the positive spirit that characterizes the organization."

Mr. Aronin founded Ovation Pharmaceuticals, Inc. in 2000 to focus on specialty therapeutics for patients with unmet medical needs. Under his leadership, the company experienced tremendous growth, having built a portfolio of 17 high-need medications for underserved patient populations, and gained wide recognition for its unique business model. In the past year, the company launched three rare disease medications, including a therapy for two difficult-to-treat epilepsies, a therapy for patients with an inherited blood clotting disorder and the first treatment for any symptom of Huntington's disease.

"We applaud Jeff for his foresight in building a business to address unmet medical needs, a commitment we share across the Lundbeck organization," Mr. Wiinberg adds. "In a relatively short time, the management team succeeded in building a dynamic pharmaceutical business – and the business is poised for even greater success that will benefit the lives of even more patients who await an effective treatment option. We want to thank Jeff for his leadership and wish him good luck in his future ventures."

-- more --

Commenting on his decision to step aside, Mr. Aronin says, “After 10 years of building the company and following the successful integration of Ovation into Lundbeck, I felt the time had come for me to move on to my next opportunity. I am proud of everything my team and I have accomplished together, particularly our success in taking the business from a concept to a thriving company that today is meeting the needs of people with diseases often overlooked by our industry.”

Effective today, Sean Nolan will assume the role of chief executive officer and Jeff Aronin will continue as strategic advisor to Lundbeck Inc.

**About Lundbeck Inc.**

Lundbeck Inc. was established in March 2009 following the acquisition of Ovation Pharmaceuticals, Inc. by H. Lundbeck A/S and has proven success in developing and commercializing high-need treatments. The company is committed to providing innovative therapies that fulfill unmet medical needs of people with CNS disorders and rare diseases for which few, if any, effective treatments are available. For more information, please visit [www.lundbeckinc.com](http://www.lundbeckinc.com).

**About H. Lundbeck A/S**

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improve the quality of life for people suffering from CNS disorders. For this purpose Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, Alzheimer’s and Parkinson’s diseases. Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark, and employs today over 5,500 people worldwide. Lundbeck is one of the world’s leading pharmaceutical companies working with CNS disorders. In 2008, the company's revenue was DKK 11.3 billion (approximately EUR 1.5 billion or USD 2.2 billion). For more information, please visit [www.lundbeck.com](http://www.lundbeck.com).

###